Product
MAZ-101association
1 clinical trial
1 indication
Indication
Allergic RhinitisClinical trial
National, Multicenter, Randomized, Double-blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER)Status: Not yet recruiting, Estimated PCD: 2024-11-01